Posted on
350
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the appointment of Jason O’Byrne as Chief Financial Officer (CFO). An accomplished executive with more than 20 years of experience within high-growth biotechnology environments, Mr. O’Byrne most recently served as Senior Vice President of Finance at Audentes Therapeutics.
“Jason’s deep experience in establishing growth-focused financial and operational infrastructures and executing successful financing strategies within the life sciences make him an ideal addition to Caribou’s executive leadership team,” said Rachel Haurwitz, Ph.D., President and Chief Executive Officer of Caribou. “We are delighted to welcome Jason to Caribou and excited to leverage his expertise in the genetic medicines space as we continue to advance our promising allogeneic CAR-T and CAR-NK cell therapies in oncology.”